JinkoSolar Announces Results of 2026 Annual General Meeting

JinkoSolar Announces Results of 2026 Annual General Meeting

SHANGRAO, China, Oct. 21, 2026 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), today announced that all shareholders resolutions proposed at the Company's 2026 annual general meeting held today were duly...

Cohesity Announces FY2026 Partner Award Winners

Cohesity Announces FY2026 Partner Award Winners

Recognition highlights top performers across Cohesity's partner ecosystem, including alliances, distributors, resellers, global system integrators, and managed service providers SINGAPORE, Oct. 21, 2026 /PRNewswire/ -- Cohesity, the leader in AI and...

Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

Metabolon Announces New Bioinformatics Application to Translate Metabolomic Biomarkers into Actionable Multiomic Hypotheses

New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpretation to generate clearer mechanistic hypotheses MORRISVILLE, N.C., Oct. 20, 2026...

TraceLink Announces $1 Million Challenge to Build Agentic Business Processes

TraceLink Announces $1 Million Challenge to Build Agentic Business Processes

Global competition invites developers, solution partners, and business process specialists worldwide to build and demonstrate innovative AI-powered business processes using TraceLink's OPUS platform BOSTON, Oct. 20, 2026 /PRNewswire/ -- TraceLink,...

Sisram Medical Announces NMPA Acceptance of Profhilo Registration Application for Facial Indication

Sisram Medical Announces NMPA Acceptance of Profhilo Registration Application for Facial Indication

Advancing Commercialization Preparations to Expand Injectables Presence in China HONG KONG, Oct. 20, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK), a global wellness group offering Energy-Based Devices ("EBD"),...

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

- Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first - in-class fixed - dose combinations. - ASC36o, a once-weekly oral amylin receptor peptide agonist, is the most advanced drug...

POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq

POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today announced that it...

Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer

Transcenta Therapeutics Announces Appointment of Ms. Jennie Ma as Chief Financial Officer

SUZHOU, China and PRINCETON, N.J., Oct. 19, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628) today announced that its Board of Directors has approved the appointment of Ms. Jennie Ma as Chief Financial Officer (CFO) of the Company. In this...

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

Akeso Announces Opening of Global Phase II Study of Ivonescimab in First-Line Clear Cell Renal Cell Carcinoma, Including Combination with Cadonilimab

HONG KONG, Oct. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") and its partner Summit Therapeutics Inc. jointly announced an international multicenter Phase II clinical study (SMT112-216 / AK112-216 / NCT07877194). Built...

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies — Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in China ROCKVILLE, Md. , Oct. 19, 2026 /PRNewswire/ -- OncoC4...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 110
  • menu
    menu